Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05499520 · ClinicalTrials.gov registry record · NA
Project RESIST: Evaluating the Effects of Anti-smoking Inoculation Messages Among Young Adult Sexual Minority Women
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 2,591
- Enrollment target
NCT05499520: Completed NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05499520 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 2,591 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05499520, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,591 participants
- Enrollment target
Study Summary
Project RESIST is an R01 study funded by NCI focused on determining the effects of using culturally tailored inoculation approaches to increase resilience to tobacco marketing influences among young adult sexual minority women ages 18-30 and incorporates critical stakeholder inputs that support later adoption and implementation. The study team is utilizing formative research to design and pre-test anti-smoking messages and two national longitudinal online survey experiments.
Primary Outcome
We used a 4-item scale on intention to quit smoking at baseline and at follow-up (immediate, one-week and one-month) among current smokers only: 1. I will make an effort to quit smoking in the next 30 days; 2. I intend to quit smoking in the next 30 days; 3. I expect to quit smoking in the next 30 days; 4. How likely is it that you will quit smoking in the next 30 days. Responses ranged on 7-point Likert-like scales. Responses were summed to create a scale for intention to quit (range from 4-28
Interventions
- OTHER Culturally Tailored Anti-Smoking Messages
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,591 participants |
| Start Date | 2022-09-21 |
| Est. Completion | 2023-08-15 |
| Phase | NA |
What the finished NCT05499520 record still lists
NCT05499520 is an interventional study that assigns participants to a tested intervention. Its 2,591 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% higher).
The record links to 0 conditions, and to 1 intervention - of which Culturally Tailored Anti-Smoking Messages is the first listed.
NCT05499520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05499520 about?
NCT05499520 is a clinical study titled "Project RESIST: Evaluating the Effects of Anti-smoking Inoculation Messages Among Young Adult Sexual Minority Women". Project RESIST is an R01 study funded by NCI focused on determining the effects of using culturally tailored inoculation approaches to increase resilience to tobacco marketing influences among young adult sexual minority women ages 18-30 and incorporates critical stakeholder inputs that support late...
What is the current status of trial NCT05499520?
This trial is currently completed. It is a NA study. The enrollment target is 2,591 participants. The study started on 2022-09-21. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT05499520?
The interventions under investigation include: Culturally Tailored Anti-Smoking Messages (OTHER).
Who is sponsoring clinical trial NCT05499520?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05499520's enrollment target sits among peer trials
2,591 44th of 2000 higher than 1,957 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI